Institutional
Novo Holdings A/S
CIK 0001388325
$1.23B
Reported AUM
22
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Novo Holdings A/S · Q1 2026
AI · grounded in 13F
Novo Holdings A/S exited its position in ZBIO, reducing its exposure by $52.6M. The fund also closed its position in INSM for $34.8M and established a new position in XENE worth $28.2M. Additionally, the fund trimmed its holdings in VALN by 54.1% and ASML by 16.7%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EWTX | EDGEWISE THERAPEUTICS INC | $35.59 | -4.41% | 133.53% | 103.26% | $168.5M | 13.65% | — | HELD |
| 2 | BN | BROOKFIELD CORP | $44.60 | -1.00% | 14.26% | 59.83% | $141.5M | 11.46% | — | HELD |
| 3 | ASML | ASML HOLDING N V | $1641.74 | -6.59% | 119.73% | 124.14% | $125.4M | 10.16% | −19,000 | −16.7% |
| 4 | MIRM | MIRUM PHARMACEUTICALS INC | $93.48 | 1.07% | 101.55% | 546.92% | $122.4M | 9.92% | +60,972 | +4.8% |
| 5 | MPLT | MAPLIGHT THERAPEUTICS INC | $28.01 | -6.94% | 65.54% | 105.50% | $74.9M | 6.07% | — | HELD |
| 6 | CRM | SALESFORCE INC | $185.66 | -1.64% | -31.86% | -22.13% | $73.4M | 5.95% | +63,000 | +19.1% |
| 7 | CRNX | CRINETICS PHARMACEUTICALS IN | $32.92 | -4.94% | -0.27% | 83.09% | $56.3M | 4.56% | −75,000 | −4.6% |
| 8 | ELVN | ENLIVEN THERAPEUTICS INC | $34.71 | -2.20% | 67.36% | 60.99% | $50.2M | 4.07% | −200,000 | −13.5% |
| 9 | PCVX | VAXCYTE INC | $47.36 | -2.87% | 28.03% | 118.45% | $50.0M | 4.05% | −56,160 | −6.1% |
| 10 | PHVS | PHARVARIS N V | $31.09 | -1.71% | 85.28% | 74.96% | $49.4M | 4.01% | — | HELD |
| 11 | AVBP | ARRIVENT BIOPHARMA INC | $30.35 | -8.28% | 29.04% | 40.90% | $44.8M | 3.63% | — | HELD |
| 12 | VRDN | VIRIDIAN THERAPEUTICS INC | $15.78 | -4.77% | 7.49% | 1.64% | $39.1M | 3.17% | −380,000 | −16.0% |
| 13 | CLDX | CELLDEX THERAPEUTICS INC NEW | $28.62 | -4.38% | 34.05% | -34.58% | $38.1M | 3.08% | — | HELD |
| 14 | APGE | APOGEE THERAPEUTICS INC | $86.92 | -4.38% | 112.10% | 278.90% | $37.9M | 3.07% | −120,000 | −21.1% |
| 15 | BMRN | BIOMARIN PHARMACEUTICAL INC | $56.77 | 0.53% | 0.21% | -26.01% | $37.3M | 3.02% | — | HELD |
| 16 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $8.64 | -13.69% | 98.62% | -65.26% | $34.0M | 2.75% | — | HELD |
| 17 | BABA | ALIBABA GROUP HLDG LTD | $121.06 | -3.88% | 3.12% | -34.69% | $32.3M | 2.62% | — | HELD |
| 18 | XENE | XENON PHARMACEUTICALS INC | $51.73 | -2.38% | 63.50% | 199.54% | $28.2M | 2.29% | +485,438 | NEW |
| 19 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $7.81 | -5.10% | -28.28% | -24.90% | $19.6M | 1.59% | +224,606 | +11.5% |
| 20 | VALN | VALNEVA SE | $5.48 | -3.35% | -11.04% | -80.83% | $6.6M | 0.54% | −1,247,579 | −54.1% |
| 21 | LNZA | LANZATECH GLOBAL INC | $6.59 | -5.72% | -77.04% | -99.32% | $2.5M | 0.21% | — | HELD |
| 22 | MQ | MARQETA INC | $3.88 | -3.72% | -29.07% | -85.54% | $1.8M | 0.15% | — | HELD |
| 23 | ZBIO | ZENAS BIOPHARMA INC | $17.47 | -4.95% | 57.10% | -17.73% | — | — | −1,450,000 | EXITED |
| 24 | INSM | INSMED INC | $94.22 | -10.20% | 27.98% | 283.01% | — | — | −200,000 | EXITED |
| 25 | IOBTQ | IO BIOTECH INC | $0.01 | 14.29% | -99.50% | -99.87% | — | — | −2,512,453 | EXITED |
Source: SEC EDGAR · accession 0001388325-26-000026. 13F discloses long positions only — shorts, foreign equities, and options are excluded.